---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-226751"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2026-05-15T20:13:34+00:00"
generated_at: "2026-05-15T20:19:21.408226+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Candel reports 39% improvement in prostate cancer-specific DFS with aglatimagene in phase 3 extended follow-up

## Summary
- Prostate cancer-specific DFS improved 39% vs placebo (HR 0.61, p=0.0031) at median 58-month follow-up.
- Consistent favorable trends in TTBF, TTM, metastasis rate, and TTNT in ITT population.
- In intermediate-risk subgroup (85% of patients), 90% reduction in time to metastasis (HR 0.1).
- Company plans to submit BLA to FDA in Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-226751
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2026-05-15T20:13:34+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000119312526226751/0001193125-26-226751-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000119312526226751/d106447d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-226751
- JSON: https://secwatch.observer/filing/0001193125-26-226751.json
- Plain text: https://secwatch.observer/filing/0001193125-26-226751.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.